DNA sequencing of heavily pre-treated multiple myeloma patients identified additional recurrent mutations and aberrations enriched at relapse including homozygous inactivation of tumor-suppressor genes TP53, RB1, FAM46C, BIRC3, TRAF314–16. Here, RB1 is linked to plasma cell myeloma.